Skip to main content

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy

NHLBI - National Heart Lung and Blood Institute

open
Rolling / OpenLast verified: 2026-06-20

About This Grant

Project Summary Dilated cardiomyopathy (DCM) is a common cause of heart failure with a severe lack of therapeutics, creating a significant clinical burden. The gene TRAPPC11 emerged from a whole transcriptome, functional screen for therapeutic targets for DCM using patient-derived human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), demonstrating reversion of contractile dysfunction upon knockdown in DCM hiPSC-CMs. TRAPPC11 is a modulator of endoplasmic reticulum (ER) stress. Since ER stress is recognized as a pathophysiological driver in DCM, my overarching hypothesis is that inhibition of TRAPPC11 would be therapeutic for DCM caused by TNNT2 mutations and possibly more broadly for other forms of DCM. This hypothesis will be tested through knockdown of TRAPPC11 in a mouse model of TNNT2 DCM and in myofilament and nonmyofilament induced DCM in hiPSC-CMs. Interestingly, single nucleotide polymorphisms (SNPs) in TRAPPC11 are associated with left ventricular hypertrophy (LVH) in response to pressure overload in African Americans. Therefore, my secondary hypothesis is that common mechanisms underlie TRAPPC11’s effect on hypertrophy induction and its therapeutic potential for DCM. Using CRISPR/Cas9 genome editing, I will test the effects of TRAPPC11 SNPs associated with LVH on ER/SR function in healthy hiPSC-CMs and introduce key SNPs into DCM hiPSC-CMs to assess their protective potential. Completion of this study will establish a translational and mechanistic rationale for targeting TRAPPC11 in DCM, and might warrant monitoring clinical outcomes of people carrying these SNPs for evidence supporting translatability of targeting TRAPPC11 to treat DCM. The training program proposed in this fellowship application was created to support my potential to become an independent investigator in the future. It will take place in the highly supportive, rich academic environment of Stanford University, where I will have access to state-of-the-art facilities and the opportunity to interact with leading cardiovascular researchers. The plan encompasses scientific technical skills, professional development skills, and both written and oral communication skills and will prepare me for writing my career development award.

Grant Summary

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy is a NHLBI - National Heart Lung and Blood Institute grant providing up to $75K for university, nonprofit, healthcare org. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $75K

Deadline

Rolling / Open

Complexity
Medium
  1. 1Confirm your organization is eligible for Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy: Frequently Asked Questions

Who is eligible for the Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy?

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy provide?

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy provides up to $75K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy deadline?

Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, NHLBI - National Heart Lung and Blood Institute, before you apply, and submit as early as possible because rolling programs can close once funds are committed.

How do you apply for the Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy?

To apply for Targeting TRAPPC11 as a therapeutic in inherited dilated cardiomyopathy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.

Browse More Grants